Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple
interacting systems. In AD, skin inflammation is caused by host–environment interactions …

Five biological drugs are currently marketed for treatment of uncontrolled severe asthma.
They all block type 2 inflammatory pathways by targeting IgE (omalizumab), the IL-5 …

Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules.
The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with≥ 20 …

Background Current systemic treatments for children younger than 6 years with moderate-to-
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …

Background Transient increases in blood eosinophil counts have been observed in
dupilumab clinical trials. Objective To assess eosinophil counts and eosinophilia-related …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic
dermatitis patients Error bars indicate the 95% confidence interval. gl This is the first study …

Abstract Rationale Type 2 (T2) asthma is characterized by airflow limitations and elevated
levels of blood and sputum eosinophils, fractional exhaled nitric oxide, IgE, and periostin …

Background Atopic dermatitis (AD) is a highly heterogeneous disease clinically and
biologically. Serum biomarkers have been utilized for endotype identification and have the …

Background Dupilumab, a monoclonal anti‐IL‐4Rα antibody, is approved for several type 2
mediated inflammatory diseases like asthma, atopic dermatitis, and diffuse type 2 chronic …